HLS Therapeutics Inc. (T:HLS)
Business Focus: Pharmaceuticals Wholesale
Apr 09, 2024 06:30 am ET
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 9, 2024 /CNW/ - HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Craig Millian, Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference, which takes place April 16-17, 2024 at the Metro Toronto Convention Centre, North Building, in downtown Toronto.
Apr 08, 2024 06:30 am ET
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
Findings Presented on VASCEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C LevelsLp(a) Results Published Simultaneously in the Journal of the American College of Cardiology (JACC)TORONTO, April 8, 2024 /CNW/ - HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, today highlighted two data presentations at the 73rd Annual Scientific Sessions of the American College of Cardiology (ACC.24) describing the effects of VASCEPA (icosapent eth
Mar 14, 2024 06:30 am ET
HLS Therapeutics Announces Fiscal 2023 Financial Results
TORONTO, March 14, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three- and twelve-month periods ended December 31, 2023. All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.
Feb 29, 2024 05:30 am ET
HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call
TORONTO, Feb. 29, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and fiscal 2023 financial results on Thursday, March 14, 2024. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian, Chief Executive Officer and Mr. John Hanna, Interim Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
Feb 06, 2024 05:30 am ET
HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan
Public reimbursement for Vascepa is now available in Ontario, Quebec, British Columbia, Saskatchewan, New Brunswick, Northwest Territories, Veterans Affairs and for the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit peoples.Approximately 14% of all Canadians live in British Columbia1.Pacific Blue Cross, British Columbia's largest private health plan, also expected to reimburse Vascepa starting in February.TORONTO, Feb. 6, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment
Dec 18, 2023 05:30 am ET
HLS Therapeutics Announces CFO Departure
John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson TORONTO, Dec. 18, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Tim Hendrickson is stepping down as CFO to pursue other interests and John Hanna, currently a director of the Company, has been appointed Interim CFO. Mr. Hendrickson will remain in his role until January 26, 2024, to support the transition and the Company will undertake a search for a per
Nov 14, 2023 04:12 pm ET
New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Witho
Analysis Also Found Icosapent Ethyl Was Associated with a 41% Reduction in Total Events Compared with PlaceboSubgroup Almost Exclusively Comprised of Patients with Established Cardiovascular DiseaseFindings Continue to Reinforce the Scientific Data and Clinical Use of Vascepa® to Reduce Cardiovascular RiskResults Presented November 12, 2023, at the American Heart Association (AHA) Scientific Sessions 2023 and Simultaneously Published in the European Heart Journal OpenTORONTO, Nov. 14, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on
Nov 09, 2023 05:30 am ET
HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid
TORONTO, Nov. 9, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three- and nine-month periods ended September 30, 2023. All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.
Oct 26, 2023 06:30 am ET
HLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference Call
TORONTO, Oct. 26, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 Fiscal 2023 financial results on Thursday, November 9, 2023. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian, Chief Executive Officer and Mr. Tim Hendrickson, Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
Sep 06, 2023 08:30 am ET
HLS Therapeutics to Present at H.C. Wainwright's 25th Annual Global Investment Conference
TORONTO, Sept. 6, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces that Craig Millian, Chief Executive Officer, will present at H.C. Wainwright's 25th Annual Global Investment Conference, which takes place September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.
Aug 14, 2023 06:30 am ET
HLS Therapeutics Announces Updates to its Credit Agreement
Term is extended, borrowing capacity increases, financial flexibility improves, and interest rates remain relatively unchanged.TORONTO, Aug. 14, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces an extension to its credit agreement, senior secured term loan, revolver facility and expansion facility (the "Amended Agreement") with a syndicate of leading bank lenders (the "Syndicate") led by JPMorgan Chase Bank as Admin Agent and Arranger, and TD Bank, as Documentation Agent,
Aug 10, 2023 06:30 am ET
HLS Therapeutics Announces Q2 Fiscal 2023 Financial Results
TORONTO, Aug. 10, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces its financial results for the three- and six-month periods ended June 30, 2023. All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.
Aug 03, 2023 06:29 pm ET
HLS Therapeutics to Host Q2 Fiscal 2023 Financial Results Conference Call
TORONTO, Aug. 3, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 Fiscal 2023 financial results on Thursday, August 10, 2023. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian, Chief Executive Officer and Mr. Tim Hendrickson, Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
Jun 22, 2023 06:30 am ET
HLS Therapeutics Announces Updates to its Board of Directors
John Welborn, Jr. is appointed Chair of the Board, succeeding Greg Gubitz, who is retiring John Hanna is appointed to the HLS Board as an independent directorTORONTO, June 22, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces today that Mr. John Hanna has been appointed to the Board of Directors (the "Board"), while Greg Gubitz, Chair of the Board, is retiring from the Board. John Welborn, a current Board member, has been appointed Chair. These changes are effective immediately.
Jun 16, 2023 06:00 pm ET
HLS Therapeutics Reports Annual Meeting Results
TORONTO, June 16, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 16, 2023.
Jun 08, 2023 06:30 am ET
HLS Therapeutics Announces Agreement with Polar Asset Management Partners and Retirement of Two Directors from the Board of Directors
HLS Directors J. Spencer Lanthier and Don DeGolyer will not be standing for re-election at the 2023 AGMDirector Greg Gubitz to retire following 2023 AGM and Polar nominee to be appointed to the BoardTORONTO, June 8, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces today that J. Spencer Lanthier and Don DeGolyer will not be standing for re-election to the HLS board of directors (the "Board") at HLS' upcoming annual meeting of shareholders to be held on June 16, 2023 (the "AGM"). Mr. Lanthier's and Mr. DeGolyer's terms as directors will expire at the conclusio
May 11, 2023 06:30 am ET
HLS Therapeutics Announces Q1 Fiscal 2023 Financial Results
TORONTO, May 11, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces its financial results for the three-month period ended March 31, 2023. All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.
May 03, 2023 06:30 am ET
HLS Therapeutics to Host Q1 Fiscal 2023 Financial Results Conference Call
TORONTO, May 3, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 Fiscal 2023 financial results on Thursday, May 11, 2023. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian, Chief Executive Officer and Mr. Tim Hendrickson, Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
Apr 21, 2023 06:30 am ET
HLS Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 21, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces that Tim Hendrickson, Chief Financial Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference, which takes place Tuesday April 25 - Wednesday April 26, 2023 at the Metro Toronto Convention Centre, North Building, in downtown Toronto.
Apr 17, 2023 07:00 am ET
HLS Therapeutics Announces CEO Transition
• Craig Millian to replace retiring CEO, Gilbert Godin, on May 1, 2023
Mar 16, 2023 06:30 am ET
HLS Therapeutics Announces Q4 and Fiscal 2022 Financial Results
TORONTO, March 16, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces its financial results for the three- and twelve-month periods ended December 31, 2022. All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.
Mar 02, 2023 05:30 am ET
HLS Therapeutics to Host Q4 and Fiscal 2022 Financial Results Conference Call
TORONTO, March 2, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and Fiscal 2022 financial results on Thursday, March 16, 2023. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Gilbert Godin, Chief Executive Officer and Mr. Tim Hendrickson, Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
Nov 29, 2022 05:30 am ET
HLS Therapeutics Announces Board Appointment
TORONTO, Nov. 29, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that Dr. Kyle Dempsey has been appointed to the board of directors of the Company (the "Board") as an independent director. Dr. Dempsey is a partner at MVM Partners ("MVM"), a healthcare focused private equity fund based in Boston, Massachusetts and London, UK.
Nov 14, 2022 05:30 am ET
HLS Therapeutics to Present at the Stifel Healthcare Conference
TORONTO, Nov. 14, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and Tim Hendrickson, CFO, will take part in a fireside chat with Stifel Healthcare analyst, Justin Keywood, at the 2022 Stifel Healthcare Conference on Wednesday November 16, 2022 at 8:35 a.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel in New York City.
Nov 10, 2022 05:30 am ET
HLS Therapeutics Announces Q3 Fiscal 2022 Financial Results and Renewal of Normal Course Issuer Bid
Q3 2022 revenue of $15.7 million, Adjusted EBITDA of $6.0 million and cash from operations of $4.2 million.Total Vascepa prescriptions grew 14% sequentially and 89% year-over-year.2,800 physicians have prescribed Vascepa, up 16% sequentially and 105% year-over-year: 9,885 patients have taken Vascepa, up 17% sequentially and 96% year-over-year.TORONTO, Nov. 10, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces its financial results for the three- and nine-month perio
Nov 07, 2022 09:30 am ET
HLS Therapeutics Highlights Key Data on the Late Breaking RESPECT-EPA Study Presented at the American Heart Association
Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore Cardiovascular Risk Reduction Benefits of Eicosapentaenoic Acid ("EPA") for Patients
Oct 27, 2022 06:30 am ET
HLS Therapeutics to Host Q3 Fiscal 2022 Financial Results Conference Call
TORONTO, Oct. 27, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 Fiscal 2022 financial results on Thursday, November 10, 2022. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Gilbert Godin, Chief Executive Officer and Mr. Tim Hendrickson, Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
Oct 03, 2022 06:30 am ET
HLS Therapeutics Announces Updates to its Credit Agreement
TORONTO, Oct. 3, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces updates to its credit agreement and senior secured term loan with its existing syndicate of bank lenders co-led by JPMorgan Chase Bank, N.A. and Silicon Valley Bank. All dollar amounts are stated in U.S. currency.
Sep 15, 2022 06:30 am ET
HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on September 22, 2022
TORONTO, Sept. 15, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series on September 22, 2022 at 12:00 PM EDT (11:00 AM CDT), to discuss its latest investor presentation. For this event, Renmark is focused on attracting participants in the U.S. Midwest region. Other interested parties are welcome to attend as well.
Aug 11, 2022 06:30 am ET
HLS Therapeutics Announces Q2 Fiscal 2022 Financial Results
Q2 2022 revenue of $15.5 million, Adjusted EBITDA of $6.2 million and cash from operations of $3.5 million.Total Vascepa prescriptions grew 88% year-over-year, reflecting sequential growth of total and new Vascepa® prescriptions in Q2 2022 of 18% and 30%, respectively.2,400 physicians have prescribed Vascepa, up 131% year-over-year and 19% sequentially: 8,500 patients have taken Vascepa, up 107% year-over-year and 19% sequentially.TORONTO, Aug. 11, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and c
Aug 02, 2022 06:30 am ET
HLS announces that Vascepa® is now reimbursed by the Saskatchewan Drug Plan
Reimbursement coverage for Vascepa in Canada is now approximately 70% for publicly covered lives and private coverage is now in excess of 95% for those that are in-labelPublic reimbursement for Vascepa is now available in Ontario, Quebec, Saskatchewan, New Brunswick, Northwest Territories and for the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit peoplesTORONTO, Aug. 2, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that, effective August 1, 2022,
Jul 28, 2022 06:30 am ET
HLS Therapeutics to Host Q2 Fiscal 2022 Financial Results Conference Call
TORONTO, July 28, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 Fiscal 2022 financial results on Thursday, August 11, 2022. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Gilbert Godin, Chief Executive Officer and Mr. Tim Hendrickson, Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
Jul 25, 2022 06:30 am ET
HLS Announces that Vascepa® is now reimbursed by Ontario's Provincial Drug Plan
Reimbursement for Vascepa in Canada is now at more than 65% for publicly covered lives and private coverage is in excess of 95% for those who are in-labelPublic reimbursement for Vascepa is now available in Ontario, Quebec, New Brunswick, Northwest Territories and for the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit peoplesTORONTO, July 25, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it has entered into a Product Listing Agreement ("PLA"
Jun 22, 2022 06:30 am ET
HLS Therapeutics Obtains Public Reimbursement for Vascepa® in New Brunswick and with other Public Payors
New Brunswick, Northwest Territories and the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit peoples will reimburse Vascepa for the reduction of cardiovascular risk in patients with established cardiovascular diseaseTORONTO, June 22, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it has successfully entered into Product Listing Agreements ("PLA") with New Brunswick, Northwest Territories and the NIHB, for the listing and public reimbursement o
Jun 17, 2022 04:00 pm ET
HLS Therapeutics Reports Annual Meeting Results
TORONTO, June 17, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 17, 2022.
Jun 15, 2022 06:30 am ET
HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on June 22, 2022
TORONTO, June 15, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series on June 22, 2022 at 12:00 PM EDT, to discuss its latest investor presentation. For this event, Renmark is focused on attracting participants in the Greater Toronto area. Other interested parties are welcome to attend as well.
Jun 01, 2022 06:30 am ET
HLS Therapeutics to Present at the 2022 Jefferies Healthcare Conference
TORONTO, June 1, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive Officer, and Tim Hendrickson, Chief Financial Officer, will present at the 2022 Jefferies Healthcare Conference, which takes place Wednesday June 8 – Friday June 10, 2022 in New York City.
May 24, 2022 05:00 pm ET
HLS Therapeutics Executive Chairman and Co-Founder Bill Wells to Retire
Co-Founder and Director Greg Gubitz appointed Chair of the Board of HLSTORONTO, May 24, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that Bill Wells, Executive Chair of the Board, has retired from the board and his executive duties at HLS effective May 23, 2022. Mr. Wells intends to focus on other business interests and has agreed to work with the Company to facilitate an orderly transition. Greg Gubitz has been appointed Chair of the Board effective immediately.
May 24, 2022 07:28 am ET
HLS Therapeutics Obtains Public Reimbursement for Vascepa® in Quebec
Quebec becomes the first province to reimburse Vascepa for the reduction of cardiovascular risk in patients with established cardiovascular diseasePrivate drug plan reimbursement for Vascepa is available in-label for cardiovascular prevention for more than 90% of privately covered lives in CanadaTORONTO, May 24, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it has successfully entered into a Product Listing Agreement ("PLA") with the Quebec Minister of Health and S
May 05, 2022 06:30 am ET
HLS Therapeutics Announces Q1 Fiscal 2022 Financial Results
Q1 2022 revenue of $14.6 million, Adjusted EBITDA of $6.3 million and cash from operations of $5.8 million.Vascepa® prescriptions grew 12% sequentially and 111% year-over-year in Q1 2022 amid Omicron COVID-19 disruptions.Achieved record levels of physician outreach and prescription activity in March as Omicron restrictions were lifted.2,025 physicians have prescribed Vascepa, up 18% sequentially and 177% year-over-year: 6,945 patients have taken Vascepa, up 14% sequentially and 139% year-over-year.Subsequent to quarter-end, completed LOI with the pCPA regarding public market reimbursement.TO
Apr 28, 2022 06:30 am ET
HLS Therapeutics to Host Q1 Fiscal 2022 Financial Results Conference Call
TORONTO, April 28, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 Fiscal 2022 financial results on Thursday, May 5, 2022. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Gilbert Godin, Chief Executive Officer and Mr. Tim Hendrickson, Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
Apr 26, 2022 06:30 am ET
HLS Therapeutics completes negotiations with pCPA for Vascepa®
Enters into Letter of Intent (LOI) that paves the way for product listing agreements for Vascepa with all of Canada's provinces and territories.Public market access is expected to be a significant catalyst to bring Vascepa to Canadians who are at-risk for cardiovascular disease.HLS updates its peak-year sales estimate to $250-300 million in revenue with Adjusted EBITDA margin of approximately 30%. Peak-year estimates expected to be reached in 2026.Conference call to be held today at 8:30am ET to discuss this announcementTORONTO, April 26, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Com
Apr 25, 2022 04:05 pm ET
HLS Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 25, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference, which takes place Monday May 2 - Tuesday May 3, 2022 at the Metro Toronto Convention Centre in downtown Toronto.
Mar 17, 2022 06:30 am ET
HLS Therapeutics Announces Q4 and Fiscal 2021 Financial Results
Q4 2021 revenue of $15.7 million, Adjusted EBITDA of $6.2 million and cash from operations of $4.0 million 2021 revenue of $60.0 million, Adjusted EBITDA of $26.3 million and cash from operations of $16.4 million Vascepa® prescriptions grew 19% sequentially in Q4 2021 - amid continued COVID-19 disruptions 1,710 physicians have prescribed Vascepa, up 25% sequentially and up from 550 at the end of 2020. 6,100 patients have used Vascepa, up 21% sequentially and up from 2,000 at the end of 2020 HLS is in the final stages of the process for public plan reimbursement of Vascepa. Final outcome is e
Mar 14, 2022 06:30 am ET
HLS Therapeutics to Host Q4 & Fiscal 2021 Financial Results Conference Call
TORONTO, March 14, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 & Fiscal 2021 financial results on Thursday, March 17, 2022. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Gilbert Godin, Chief Executive Officer and Mr. Tim Hendrickson, Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
Jan 12, 2022 05:30 am ET
HLS Therapeutics to Present at the Sidoti Investor Conference
TORONTO, Jan. 12, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive Officer, and Tim Hendrickson, Chief Financial Officer, will present and host one-on-one meetings with investors at the Sidoti Winter Virtual Investor Conference, taking place January 19-20, 2022. The conference will be held in a virtual meeting format.
Dec 20, 2021 05:30 am ET
HLS Therapeutics Establishes Automatic Share Purchase Plan
TORONTO, Dec. 20, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that in connection with its previously announced normal course issuer bid ("NCIB") to purchase up to an aggregate of 1,622,559 of its issued and outstanding common shares (each, a "Common Share"), it has entered into an automatic share purchase plan ("ASPP") with a designated broker, Haywood Securities Inc. The ASPP allows for the purchase of Common Shares under the NCIB at any time, including when HLS would
Dec 01, 2021 05:30 am ET
HLS Therapeutics to Present at Stifel GMP's Future of Healthcare Conference
TORONTO, Dec. 1, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive Officer, and Tim Hendrickson, Chief Financial Officer, will present at Stifel GMP's 2nd Annual Future of Healthcare Conference on Wednesday December 8, 2021 at 10:30 a.m. Eastern Standard Time. The conference will be held in a virtual meeting format.
Nov 11, 2021 05:30 am ET
HLS Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
TORONTO, Nov. 11, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive Officer, and Tim Hendrickson, Chief Financial Officer, will present at the Stifel 2021 Virtual Healthcare Conference on Tuesday November 16, 2021 at 8:40 a.m. Eastern Standard Time. The conference will be held in a virtual meeting format.
Nov 04, 2021 06:30 am ET
HLS Therapeutics Announces Q3 Fiscal 2021 Financial Results
Q3 2021 revenue of $15.1 million and Adjusted EBITDA of $6.9 million, up 15% and 53%, respectively, from Q3 2020 Generated strong Vascepa® prescription growth - amid persistent COVID-19 disruptions - achieving increases in prescribers and patients of 30% and 23%, respectively, from the end of Q2 2021 Vascepa revenue increased 33% sequentially from Q2 2021 Generated cash from operations of $12.5 million year-to-date compared to $3.5 million in the same period last year Announced promotional agreement with Pfizer for Vascepa in Canada TORONTO, Nov. 4, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS"
Oct 21, 2021 06:30 am ET
HLS Therapeutics to Host Q3 2021 Financial Results Conference Call
TORONTO, Oct. 21, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 2021 financial results on Thursday, November 4, 2021. The Company will hold a conference call that same day at 8:30 a.m. EDT to discuss its results. The call will be hosted by Mr. Gilbert Godin, Chief Executive Officer and Mr. Tim Hendrickson, Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
Oct 04, 2021 06:30 am ET
HLS Therapeutics to Participate in Two Virtual Non-Deal Roadshows
TORONTO, Oct. 4, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in two upcoming live Virtual Non-Deal Roadshows hosted by Renmark Financial Communications Inc.
Aug 16, 2021 06:30 am ET
HLS Therapeutics Announces Promotional Agreement with Pfizer for Vascepa® in Canada
Agreement enables rapid, efficient and impactful expansion to the primary care physician audience. HLS will continue to focus primarily on specialists while Pfizer will focus primarily on primary care physicians. Pfizer is a well-respected partner with a shared passion for innovation in Cardiology and a rich heritage in the space. TORONTO, Aug. 16, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces that effective August 13, 2021 it has entered into a promotional se
Aug 05, 2021 06:30 am ET
HLS Therapeutics Announces Second Quarter Fiscal 2021 Financial Results
Q2 2021 revenue of $14.9 million and Adjusted EBITDA of $6.6 million, up 19% and 36%, respectively, from Q2 2020 Generated strong Vascepa® prescription growth - amid persistent COVID-19 disruptions - achieving 4,100 patients and 1,050 prescribers at end of Q2, which are increases of 41% and 44%, respectively, from the end of Q1 2021 Vascepa revenue increased 42% sequentially from Q1 2021 Generated cash from operations of $8.9 million year-to-date compared to $1.1 million in the same period last year TORONTO, Aug. 5, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a p
Aug 04, 2021 06:30 am ET
HLS Therapeutics to Present at the Canaccord Genuity 41st Annual Growth Conference
TORONTO, Aug. 4, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and Tim Hendrickson, CFO, will present at the Canaccord Genuity 41st Annual Growth Conference on Thursday August 12, 2021 at 11:00 a.m. Eastern Daylight Time. The conference will be held in a virtual meeting format.
Jul 22, 2021 06:30 am ET
HLS Therapeutics to Host Q2 2021 Financial Results Conference Call
TORONTO, July 22, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 2021 financial results on Thursday, August 5, 2021. The Company will hold a conference call that same day at 8:30 a.m. EDT to discuss its results. The call will be hosted by Mr. Gilbert Godin, Chief Executive Officer and Mr. Tim Hendrickson, Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
Jun 18, 2021 04:15 pm ET
HLS Therapeutics Reports Annual Meeting Results
TORONTO, June 18, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 18, 2021.
Jun 15, 2021 06:30 am ET
HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on June 16, 2021
TORONTO, June 15, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on June 16, 2021 at 11:00 AM EDT (10:00 AM CDT). For this event, Renmark is focused on attracting participants in the Greater Chicago area. Other interested parties are welcome to attend as well.
Jun 09, 2021 06:30 am ET
HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on June 10, 2021
TORONTO, June 9, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on June 10, 2021 at 10:00 AM EDT (7:00 AM PDT). HLS welcomes stakeholders, investors, and other individual followers to register and attend this live event.
May 26, 2021 06:30 am ET
HLS Therapeutics Announces Participation at Upcoming Investor Conferences
TORONTO, May 26, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and Tim Hendrickson, CFO, will participate in two upcoming investor conferences in the month of June.
May 06, 2021 06:30 am ET
HLS Therapeutics Announces First Quarter Fiscal 2021 Financial Results
Q1 2021 revenue of $14.3 million, Adjusted EBITDA of $6.7 million and cash from operations of $7.2 million, up $0.4 million, $0.6 million and $1.8 million, respectively, from Q1 2020 Vascepa revenue growth drives higher total revenues offsetting impact of additional Clozaril trade purchasing in the early stages of the pandemic in Q1 2020 Generated strong Vascepa® prescription growth - amid persistent COVID-19 disruptions - achieving 2,900 patients and 730 prescribers at end of Q1, which are increases of 40% and 33%, respectively, from the end of Q4 Achieved Vascepa reimbursement with private
Apr 22, 2021 06:30 am ET
HLS Therapeutics to Host Q1 2021 Financial Results Conference Call
TORONTO, April 22, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2021 financial results on Thursday, May 6, 2021. The Company will hold a conference call that same day at 8:30 a.m. EST to discuss its results. The call will be hosted by Mr. Gilbert Godin, Chief Executive Officer and Mr. Tim Hendrickson, Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
Apr 15, 2021 06:30 am ET
HLS Therapeutics Announces Participation in Upcoming Conferences
TORONTO, April 15, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and Tim Hendrickson, CFO, will participate in two upcoming investor conferences: the Bloom Burton & Co. Healthcare Investor Conference and the Stifel 2021 Canada Cross Sector Insight Conference.
Apr 01, 2021 06:30 am ET
HLS Therapeutics Comments on Rule Enacted by Quebec Health Minister Christian Dubé and the Absence of an Exception for New Refractory Schizophrenic Patients
DORVAL, QC, April 1, 2021 /CNW Telbec/ - HLS Therapeutics Inc. regrets the adoption of a new regulation, published yesterday in the Gazette officielle du Québec, which limits access to a support program for new patients suffering from refractory schizophrenia, and urgently requests a meeting with the Quebec Minister of Health and Social Services Christian Dubé.
Mar 29, 2021 06:30 am ET
HLS Therapeutics Announces that Icosapent Ethyl (Vascepa®) is Included in the 2021 Canadian Cardiovascular Society (CCS) Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascu
CCS dyslipidemia management guidelines published in the Canadian Journal of Cardiology (CJC) on March 26, 2021 Strong recommendation for the use of icosapent ethyl for Primary Prevention (diabetes and ≥1 cardiovascular disease (CVD) risk factors) and Secondary Prevention (atherosclerotic cardiovascular disease (ASCVD)) Guidelines do not recommend the use of over-the-counter omega-3 polyunsaturated fatty acids supplements to reduce CVD risk TORONTO, March 29, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous
Mar 18, 2021 06:30 am ET
HLS Therapeutics Announces Fourth Quarter and Fiscal 2020 Financial Results
Fourth quarter revenue of $16.5 million, Adjusted EBITDA of $8.7 million and cash from operations of $5.8 million Produced strong Vascepa® prescription growth amid COVID-19 challenges: more than 2,000 patients and more than 550 prescribers at end of Q4, which are increases of more than 70% and 55%, respectively, from the end of Q3 As of March 18, 2021 , reached agreement with private insurers in Canada, representing > 90% of privately covered lives, to provide reimbursement coverage for Vascepa TORONTO, March 18, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a
Mar 17, 2021 11:34 am ET
HLS Therapeutics Announces that VASCEPA® (Icosapent Ethyl) is Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Pr
28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk Consistent reductions in overall stroke and in ischemic stroke observed across multiple subgroups Administration of pure icosapent ethyl, VASCEPA, represents a novel clinical approach to stroke reduction TORONTO, March 17, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a speci
Mar 04, 2021 05:30 am ET
HLS Therapeutics to Host Q4 and Fiscal 2020 Financial Results Conference Call
TORONTO, March 4, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and fiscal 2020 financial results by press release at 6:30 a.m. EST on Thursday, March 18, 2021. The Company will hold a conference call that same day at 8:30 a.m. EST to discuss its results. The call will be hosted by Mr. Gilbert Godin, Chief Executive Officer and Mr. Tim Hendrickson, Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
Feb 23, 2021 05:30 am ET
HLS Therapeutics to Participate in Upcoming Virtual Non-Deal Roadshow on February 25, 2021
TORONTO, Feb. 23, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it will participate in an upcoming event as part of Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series. For this event, Renmark is focused on attracting participants in the Greater Boston area. Other interested parties are welcome to attend as well.
Feb 16, 2021 03:30 pm ET
HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on February 18, 2021
TORONTO, Feb. 16, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on February 18, 2021 at 1:00 PM EST (10:00 AM PST). HLS welcomes stakeholders, investors, and other individual followers to register and attend this live event.
Feb 16, 2021 05:30 am ET
HLS Therapeutics Provides Update on Private and Public Payer Reimbursement for Vascepa®
Private payer health plan coverage in Canada for Vascepa is expected to reach more than 80% by the end of February 2021, up from 50% in November 2020 Coverage effective for statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to established cardiovascular disease, or diabetics with risk factors Active negotiations have also begun with the pan-Canadian Pharmaceutical Alliance (pCPA) for reimbursement of Vascepa by publicly funded health plans TORONTO, Feb. 16, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty
Jan 28, 2021 05:30 am ET
VASCEPA® (Icosapent Ethyl) Receives Further Inclusions in Guidelines from International Medical Societies for its Role in Reducing the Risk of Cardiovascular Events
Vascepa included in Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology1 Chinese Society of Cardiology updated Guidelines now include Vascepa in its Prevention of Cardiovascular Diseases Vascepa is now included in the treatment guidelines or otherwise recommended for use by 13 medical associations worldwide including Thrombosis Canada2-14 HLS expects the Canadian Cardiovascular Society will review and potentially update its lipid management guidelines in 2021 TORONTO, Jan. 28, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "
Jan 04, 2021 05:30 am ET
HLS Therapeutics Announces Final Redemption of Preferred Shares
- Redemption completes last step resulting from the 2018 Plan of Arrangement
Dec 21, 2020 08:35 am ET
Life Sciences Company Investor Presentations Now Available for On-Demand Viewing
Life Sciences Investor Forum today announced that the presentations from the December 17th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive...
Dec 21, 2020 05:30 am ET
HLS Therapeutics Announces Board Appointment
TORONTO, Dec. 21, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that John L. Welborn, Jr., Managing Director, Co-Chief Investment Officer for Stadium Capital Management, LLC ("Stadium"), will be nominated for election to the board of directors of the Company (the "Board") as an independent director. Stadium and its affiliates are the largest shareholder of HLS and own approximately 18.8% of the Company's issued and outstanding common shares.
Dec 16, 2020 05:30 am ET
HLS Therapeutics Announces Update on Health Canada Filings for MyCare and Trinomia
Health Canada approves MyCare Psychiatry Lab Assays for use in diagnostic lab settings to measure blood levels in patients prescribed six of the most common antipsychotic drugs MyCare Insite point-of-care (POC) device, which measures the level of antipsychotic drugs in patients' blood, is under review and could be approved in H1-2021 Health Canada issued a Notice of Deficiency for Trinomia TORONTO, Dec. 16, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces updates
Dec 14, 2020 08:35 am ET
HLS Therapeutics to Webcast Live at Life Sciences Investor Forum December 17th
HLS Therapeutics Inc. (“HLS” or the “Company”) (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, today announced that Gilbert Godin, CEO, will present live at LifeSciencesInvestorForum.com...
Dec 14, 2020 08:28 am ET
Virtual Conference for Life Sciences Companies Broadcast Live December 17th, 2020
Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
Dec 14, 2020 05:30 am ET
HLS Therapeutics Reports Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with Vascepa® (Icosapent Ethyl)
Results presented in Late Breaker session at National Lipid Association Scientific Sessions 2020 Vascepa COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability data using Vascepa loading dose Vascepa administration resulted in a significant 52% reduction of the total patient-reported symptom outcome prevalence score as compared to a 24% reduction in the usual care group Larger follow
Nov 19, 2020 05:30 am ET
HLS Therapeutics Establishes Automatic Share Purchase Plan
TORONTO, Nov. 19, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that in connection with its previously announced normal course issuer bid ("NCIB") to purchase up to an aggregate of 1,587,193 of its issued and outstanding common shares (each, a "Common Share"), it has entered into an automatic share purchase plan ("ASPP") with a designated broker, Haywood Securities Inc. The ASPP allows for the purchase of Common Shares under the NCIB at any time, including when
Nov 17, 2020 05:30 am ET
HLS Therapeutics Announces Health Canada Approval of PERSERIS® for the Treatment of Schizophrenia
first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia once-monthly dosing may help improve treatment compliance PERSERIS is a first-line treatment option for schizophrenia and is commercially complementary to Clozaril®, which is for treatment resistant schizophrenia TORONTO, Nov. 17, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that Health Canada has approved the use of PERSERIS® (risperidone for extended-release inject
Nov 16, 2020 05:30 am ET
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting Procedures
Results from Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Association's Virtual Scientific Sessions 2020 VASCEPA®, compared with placebo, significantly reduced primary composite first and total MACE (major adverse cardiovascular events) in post hoc exploratory analyses of patients with a history of Coronary Artery Bypass Grafting (commonly referred to as Bypass Surgery) by 24% and 36%, respectively, and key secondary composite first hard MACE, comprised of heart attacks, stroke and cardiovascular death, by 31% The use of VASCEPA resulted in absolute ris
Nov 12, 2020 05:30 am ET
HLS Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
TORONTO, Nov. 12, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday November 17, 2020 at 2:40 p.m. Eastern Daylight Time.
Nov 05, 2020 05:30 am ET
HLS Therapeutics Announces Q3 2020 Financial Results and Normal Course Issuer Bid
Revenue of $13.1 million, Adjusted EBITDA of $4.5 million and cash from operations of $2.4 million Produced strong Vascepa prescription growth amid COVID-19 challenges: approximately 1,200 patients and more than 350 prescribers at end of Q3, which are increases of 124% and 88%, respectively, versus Q2 Increased private insurance coverage for Vascepa in Canada to approximately 50% of privately covered lives as of today's date Acquired a portfolio of four royalty interests that is expected to generate average annual Adjusted EBITDA of $11.0 million per year for a ten-year period Announces Norm
Oct 27, 2020 06:30 am ET
HLS Therapeutics to Host Q3 2020 Financial Results Conference Call
TORONTO, Oct. 27, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 2020 financial results by press release at 6:30 a.m. Eastern Daylight Time on Thursday, November 5, 2020. The Company will hold a conference call that same day at 8:30 a.m. Eastern Daylight Time to discuss its results. The call will be hosted by Mr. Gilbert Godin, President and Chief Executive Officer and Mr. Tim Hendrickson, Chief Financial Officer.
Oct 22, 2020 06:30 am ET
HLS Therapeutics Highlights Latest Icosapent Ethyl Research Presented at the Canadian Cardiovascular Congress
In vitro data presented provides additional insight into potential mechanisms by which Vascepa reduces cardiovascular risk TORONTO, Oct. 22, 2020 /CNW/ - "The Vascepa story continues to unfold as we learn more about how icosapent ethyl acts on a cellular level," said Gilbert Godin, President and CEO of HLS Therapeutics. "The new in vitro data presented at CCC may help us to further understand the possible ways by which Vascepa works."
Sep 30, 2020 01:41 pm ET
IIROC Trading Halt - HLS
TORONTO, Sept. 30, 2020 /CNW/ - The following issues have been halted by IIROC:
Sep 30, 2020 01:33 pm ET
IIROC Trade Resumption - HLS
TORONTO, Sept. 30, 2020 /CNW/ - Trading resumes in:
Sep 30, 2020 01:20 pm ET
HLS Therapeutics Acquires Portfolio of Four Royalty Interests
HLS anticipates the portfolio will generate sustained and diversified revenues and cash flows Portfolio forecasted to generate an IRR in excess of 20% per year for at least ten years Compelling financial dynamics: purchase price reflects a multiple of 5.5X Adjusted EBITDA, assuming payment of all contingent milestone payments. Products are marketed by global blue-chip healthcare organizations that are leaders in their sectors TORONTO, Sept. 30, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and ca
Sep 03, 2020 01:29 pm ET
HLS Therapeutics Comments on U.S. Court of Appeals Decision in Amarin Patent Litigation
U.S. decision does not relate to Vascepa in Canada Vascepa was granted 8 years of data exclusivity by Health Canada upon approval Vascepa patent estate could potentially extend protection in Canada to 2039 TORONTO, Sept. 3, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, comments on the U.S. Court of Appeals for the Federal Circuit ruling in Amarin Corporation plc's ("Amarin") ongoing patent litigation. The Court upheld the March ruling by the U.S. District Court for the
Aug 31, 2020 06:30 am ET
VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ESC Congress 2020
Primary endpoint of slowed coronary plaque progression reported to have been met with VASCEPA Significant coronary plaque regression of low attenuation plaque (LAP) reported with VASCEPA provides further insight to potential mechanisms of action VASCEPA is the first and only agent studied on top of statins reported to exhibit coronary plaque regression in hypertriglyceridemic patients TORONTO, Aug. 31, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announced today that
Aug 07, 2020 06:30 am ET
HLS Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference
TORONTO, Aug. 7, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, President and Chief Operating Officer, will present at the Canaccord Genuity 40th Annual Growth Conference on Wednesday August 12, 2020 at 1:30 p.m. Eastern Daylight Time. The conference will be held in a virtual meeting format.
Aug 06, 2020 06:30 am ET
HLS Therapeutics Announces Q2 2020 Financial Results
Revenue of $12.6 million and Adjusted EBITDA of $4.8 million Increasing peak-year sales estimate for Vascepa to C$275-325 million Clozaril's Canadian patient count and sales in local currency increase 2.3% and 2.5%, respectively, demonstrating resilience during the COVID-19 pandemic Privately covered lives for Vascepa in Canada increase to 40% as of today's date CEO succession: Gilbert Godin, President & COO, named CEO to replace Greg Gubitz who is retiring TORONTO, Aug. 6, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing
Jul 30, 2020 06:30 am ET
HLS Therapeutics to Host Q2 2020 Financial Results Conference Call
TORONTO, July 30, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 2020 financial results by press release at 6:30 a.m. Eastern Time on Thursday, August 6, 2020. The Company will hold a conference call that same day at 8:30 a.m. Eastern Daylight Time to discuss its results. The call will be hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Mr. Tim Hendrickson, Chief Financial Officer.
Jul 21, 2020 07:58 am ET
IIROC Trade Resumption - HLS
TORONTO, July 21, 2020 /CNW/ - Trading resumes in:
Jul 20, 2020 04:30 pm ET
HLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa® (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory price
CADTH recommends Vascepa be reimbursed for patients with established cardiovascular disease under certain conditions. PMPRB notifies HLS that following PMPRB's review, Vascepa's introductory price submission did not trigger the pricing investigation criteria. HLS reaffirms its peak-year sales forecast for Vascepa. HLS management to hold investor update conference call with accompanying slides today at 5:30 p.m. EDT. TORONTO, July 20, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascul
Jul 20, 2020 04:04 pm ET
IIROC Trading Halt - HLS
TORONTO, July 20, 2020 /CNW/ - The following issues have been halted by IIROC:
Jun 19, 2020 02:00 pm ET
HLS Therapeutics Reports Annual Meeting Results
TORONTO, June 19, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting of Shareholders held on June 19, 2020 in Toronto, Ontario.
Jun 17, 2020 06:30 am ET
HLS Therapeutics to Present at the Raymond James Human Health Innovation Conference
TORONTO, June 17, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, President and Chief Operating Officer, will present at the Raymond James Human Health Innovation Conference on Thursday June 18, 2020 at 11:40 a.m. Eastern Daylight Time. The conference will be held in a virtual meeting format.
Jun 10, 2020 06:30 am ET
HLS Therapeutics Confirms Annual Shareholders' Meeting
TORONTO, ON, June 10, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, confirms that its Annual Meeting of Shareholders (the "Meeting") will take place at the offices of Blake, Cassels & Graydon LLP, 199 Bay Street, Commerce Court West, Suite 4000, Toronto, Ontario, on Friday June 19, 2020 at 10:00 a.m. (Toronto time).
Jun 01, 2020 05:00 pm ET
HLS Therapeutics to Present at the Jefferies Virtual Healthcare Conference
TORONTO, June 1, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Greg Gubitz, Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday June 3, 2020 at 9:00 a.m. Eastern Daylight Time.
Jun 01, 2020 06:30 am ET
HLS Therapeutics to Become Distributor of the Saladax MyCare™ Psychiatry Line including the Insite Point-of-Care Device and Antipsychotic Reagents
The MyCare Insite is a point-of-care (POC) device that uses just a single drop of blood to measure the most commonly used antipsychotic drugs in patients' blood The MyCare Psychiatry Clozapine Assay Test Kit has been granted Market Authorization by the U.S FDA; no such product exists in the Canadian market today Tests for 5 additional POC antipsychotics are in the final stages of development Device is complementary to the Company's CNS/Psychiatry business TORONTO, June 1, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on ce
May 21, 2020 04:07 pm ET
HLS Therapeutics Supports Trial to Investigate the Effects of Vascepa® (Icosapent Ethyl) against COVID-19
TORONTO, May 21, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that in collaboration with Amarin Corporation (NASDAQ:AMRN) it is supporting a trial to investigate the effects of Vascepa® (icosapent ethyl, or "IPE") on inflammatory biomarkers in individuals with COVID-19. The trial sponsored by the Canadian Medical and Surgical Knowledge Translation Research Group, is being led by Dr. Subodh Verma MD, PhD, FRCSC, FAHA, a cardiac surgeon‐scientist at St Michael's
May 07, 2020 06:30 am ET
HLS Therapeutics Announces Q1 2020 Financial Results
Revenue of $13.9 million, Adjusted EBITDA of $6.1 million and Cash from Operations of $5.3 million Launched Vascepa® in the Canadian market Vascepa added to Health Canada's Register of Innovative Drugs; will benefit from data protection for eight years New Drug Submissions for PERSERIS® and Trinomia® accepted by Health Canada TORONTO, May 7, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces its financial results for the three-month period ended March 31, 2020 ("Q1
Apr 30, 2020 06:30 am ET
HLS Therapeutics to Host Q1 2020 Financial Results Conference Call
TORONTO, April 30, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2020 financial results by press release at 6:30 a.m. Eastern Time on Thursday, May 7, 2020. The Company will hold a conference call that same day at 8:30 a.m. Eastern Time to discuss its results. The call will be hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Mr. Tim Hendrickson, Chief Financial Officer. To participate on the call, please enter a dial-in number below and then enter the Conference ID
Mar 31, 2020 07:30 am ET
HLS Therapeutics Comments on U.S. District Court Decision on Amarin Patents
TORONTO, March 31, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, comments on the United States District Court for the District of Nevada's ruling in favor of the generic companies in Amarin Corporation plc's ("Amarin") patent litigation against two generic filers for Amarin's VASCEPA® (icosapent ethyl). HLS has in-licensed the exclusive rights to VASCEPA for the Canadian market from Amarin.
Mar 19, 2020 06:30 am ET
HLS Therapeutics Announces Fourth Quarter and Fiscal 2019 Financial Results
Revenue of $54.2 million, Adjusted EBITDA of $31.6 million and Cash from Operations of $26.4 million Received approval from Health Canada for Vascepa® to reduce the risk of cardiovascular events Received medical device license from Health Canada for the CSAN® Pronto™ point-of-care blood testing medical device TORONTO, March 19, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces its financial results for the three- and twelve-month periods ended December 31, 2019 (
Feb 27, 2020 03:00 pm ET
HLS Therapeutics to Host Q4 and Fiscal 2019 Financial Results Conference Call
TORONTO, Feb. 27, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its fourth quarter and fiscal 2019 financial results by press release at 6:30 a.m. Eastern Time on Thursday, March 19, 2020. The Company will hold a conference call that same day at 8:30 a.m. Eastern Time to discuss its results. The call will be hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Mr. Tim Hendrick
Jan 28, 2020 05:30 am ET
HLS Therapeutics Provides Investor Update on the Canadian Launch of Vascepa® (Icosapent Ethyl)
Vascepa to be available on or about February 18, 2020, supported by a national Cardiovascular salesforce Vascepa becomes the first and only Health Canada-approved medication for reducing cardiovascular risk beyond cholesterol-lowering therapy in the studied high-risk patients approved for treatment Vascepa is supported by data from the REDUCE-IT® trial, an international 8,179 patient outcomes study that showed a 25% placebo-controlled risk reduction in the first occurrence of major adverse cardiovascular events Cardiovascular disease is the number one killer globally1 and HLS is taking steps
Jan 23, 2020 05:30 am ET
HLS Therapeutics Files New Drug Submission for PERSERIS® in Canada
If approved by Health Canada, PERSERIS would become the first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia
Jan 07, 2020 06:51 am ET
IIROC Trade Resumption - HLS
TORONTO, Jan. 7, 2020 /CNW/ - Trading resumes in:
Jan 06, 2020 02:30 pm ET
HLS Therapeutics Announces 8 Years of Data Protection for Vascepa®
Peak-year sales estimate increases to CAD$200-300 million, from CAD$150-250 million Commercial launch expected to take place in the mid-February 2020 timeframe Vascepa is the subject of numerous Canadian issued and pending patents with expiration dates which could extend to 2039 TORONTO, Jan. 6, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that today Vascepa® was added to Health Canada's Register of Innovative Drugs and as a result it will benefit from data p
Jan 06, 2020 01:41 pm ET
IIROC Trading Halt - HLS
TORONTO, Jan. 6, 2020 /CNW/ - The following issues have been halted by IIROC:
Dec 31, 2019 12:14 pm ET
IIROC Trade Resumption - HLS
TORONTO, Dec. 31, 2019 /CNW/ - Trading resumes in:
Dec 31, 2019 12:00 pm ET
HLS Therapeutics Announces Health Canada Approval for Vascepa® to Reduce the Risk of Cardiovascular Events
Health Canada approval follows priority review for VascepaVascepa becomes the first and only HC-approved medication for reducing cardiovascular risk beyond cholesterol lowering therapy in the studied high-risk patients approved for treatmentCommercial launch expected to take place in the mid-February 2020 timeframeVascepa is supported by data from the REDUCE-IT® trial, an international, 8,179 patient outcomes study that showed a 25% placebo-controlled risk reduction in the first occurrence of major adverse cardiovascular eventsVascepa is the subject of numerous Canadian issued and pending pa
Dec 31, 2019 11:07 am ET
IIROC Trading Halt - HLS
TORONTO, Dec. 31, 2019 /CNW/ - The following issues have been halted by IIROC:
Nov 15, 2019 05:30 am ET
HLS Therapeutics Reports on U.S. FDA Advisory Committee Recommendation for Vascepa
TORONTO, Nov. 15, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that the Endocrinologic and Metabolic Drugs Advisory Committee ("EMDAC") of the U.S. Food and Drug Administration ("FDA") yesterday voted unanimously (16-0) that Amarin Corporation plc (NASDAQ: AMRN) provided sufficient evidence of efficacy and safety to support the approval of Vascepa® (icosapent ethyl) capsules for an indication and label expansion to reduce the risk of cardiovascular events in h
Nov 07, 2019 05:30 am ET
HLS Therapeutics Announces Q3 2019 Financial Results
Revenue of $13.4 million, Adjusted EBITDA of $8.0 million and Cash from Operations of $6.8 million Paid a quarterly dividend of C$0.05 per outstanding common share Subsequent to quarter-end, received approval from Health Canada for the CSAN® Pronto™ point-of-care blood testing medical device TORONTO, Nov. 7, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces its financial results for the three- and nine-month periods ended September 30, 2019 ("Q3 2019" and "YTD 20
Oct 24, 2019 06:30 am ET
HLS Therapeutics to Host Q3 2019 Financial Results Conference Call
TORONTO, Oct. 24, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its third quarter 2019 financial results by press release at 6:30 a.m. Eastern Time on Thursday, November 7, 2019. The Company will hold a conference call that same day at 8:30 a.m. Eastern Time to discuss its results. The call will be hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Mr. Tim Hendrickson, Chief
Oct 17, 2019 06:30 am ET
HLS Therapeutics announces Health Canada grants medical device license for White Blood Cell Point-of-Care Device to be marketed as CSAN® PRONTO™
From a single drop of blood from the tip of a finger, Athelas One WBC System generates white blood cell counts and neutrophils percentages in minutesThe device could help lower the most commonly cited barrier for using Clozaril® among those who could benefit from itHLS has the exclusive Canadian rights to the device in the field of schizophrenia under a licensing agreement with Athelas, Inc. ("Athelas")The device will become part of the Clozaril Support and Assistance Network (CSAN®) and made available to Canadian Institutions and HCPs under the name CSAN® Pronto™ TORONTO, Oct. 17, 2019 /CN
Aug 08, 2019 06:30 am ET
HLS Therapeutics Announces Q2 2019 Financial Results
Revenue of $13.6 million, Adjusted EBITDA of $8.1 million and Cash from Operations of $9.0 million Filed the New Drug Submission for Vascepa® with Health Canada after having been granted Priority Review status Completed a C$50.0 million (US$37.3 million) bought-deal offering In - licensed the Canadian rights to PERSERIS™, a novel long-acting injectable risperidone product for the treatment of schizophrenia Paid a quarterly dividend of C$0.05 per outstanding common share TORONTO, Aug. 8, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical compan
Jul 25, 2019 06:30 am ET
HLS Therapeutics to Host Q2 2019 Financial Results Conference Call
TORONTO, July 25, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its second quarter 2019 financial results by press release at 6:30 a.m. Eastern Time on Thursday, August 8, 2019. The Company will hold a conference call that same day at 8:30 a.m. Eastern Time to discuss its results. The call will be hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Mr. Tim Hendrickson,
Jun 21, 2019 12:40 pm ET
HLS Therapeutics Reports Annual Meeting Results
TORONTO, June 21, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces voting results from its Annual Meeting of Shareholders held on June 21, 2019 in Toronto, Ontario.
Jun 05, 2019 08:51 am ET
HLS Therapeutics Announces Closing of $50 Million Bought Deal Offering
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./
May 30, 2019 06:30 am ET
HLS Therapeutics to Present at Two Upcoming Conferences
TORONTO, May 30, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will present at the following conferences:
May 15, 2019 08:11 am ET
IIROC Trade Resumption - HLS
TORONTO, May 15, 2019 /CNW/ - Trading resumes in:
May 14, 2019 04:18 pm ET
HLS Therapeutics Announces $43,500,000 Million Bought Deal Offering
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./
May 14, 2019 04:11 pm ET
IIROC Trading Halt - HLS
TORONTO, May 14, 2019 /CNW/ - The following issues have been halted by IIROC:
May 09, 2019 06:30 am ET
HLS Therapeutics Announces Q1 2019 Financial Results
Revenue of $13.2 million, Adjusted EBITDA of $8.3 million and Cash from Operations of $8.3 million Granted priority review status for Vascepa™ by Health Canada, which could reduce the review period for the drug by up to four-and-a-half months. Announced the filing of the New Drug Submission ("NDS") for Vascepa with Health Canada on April 29, 2019 Announced the in-licensing of the exclusive Canadian rights for CSAN® Pronto™, a point-of-care medical device intended to simplify the blood monitoring process for patients that are prescribed Clozaril® Subsequent to quarter-end, entered into a lice
Apr 29, 2019 06:00 am ET
HLS Therapeutics Files New Drug Submission for Vascepa® in Canada
Cardiovascular disease is the leading cause of death globally1 NDS for Vascepa is supported by data from the REDUCE-IT™ trial, an international, multi-center cardiovascular outcomes study that showed a 25% placebo-controlled risk reduction in the first occurrence of major adverse cardiovascular events Vascepa has been granted priority review status by Health Canada, which could reduce review time by up to four-and-a-half months TORONTO, April 29, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and
Apr 25, 2019 06:30 am ET
HLS Therapeutics to Host Q1 2019 Financial Results Conference Call
TORONTO, April 25, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its first quarter 2019 financial results by press release at 6:30 a.m. Eastern Time on Thursday, May 9, 2019. The Company will hold a conference call that same day at 8:30 a.m. Eastern Time to discuss its results. The call will be hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Mr. Tim Hendrickson, Chief Fin
Apr 23, 2019 06:30 am ET
HLS Therapeutics to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 23, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Greg Gubitz, CEO, will present at the Bloom Burton & Co. Healthcare Investor Conference, which takes place Tuesday April 30 – Wednesday May 1, 2019 at the Metro Toronto Convention Centre in downtown Toronto. HLS will present on April 30, 2019, at 1:30 p.m. Eastern Time. The Company's presentation will be webcast at: http://wsw.com/webcast/bloomburton4/hls.v/
Apr 01, 2019 07:32 am ET
IIROC Trade Resumption - HLS
TORONTO, April 1, 2019 /CNW/ - Trading resumes in:
Mar 29, 2019 05:45 pm ET
Vascepa® Granted Priority Review Status from Health Canada
Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that its licensee in Canada, HLS Therapeutics Inc. (TSX:HLS), has received formal confirmation from Health Canada that the...
Mar 29, 2019 03:16 pm ET
HLS Therapeutics Granted Priority Review Status from Health Canada for Vascepa®
Cardiovascular disease is the leading cause of death globally1 HLS New Drug Submission (NDS) for Vascepa is supported by data from the REDUCE-IT™ trial, an international, multi-center cardiovascular outcomes study that showed a 25% placebo-controlled risk reduction in the first occurrence of major adverse cardiovascular events (MACE) HLS NDS filing to occur in April 2019 Priority review status can reduce review time by more than four-and-a-half months TORONTO, March 29, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on cent
Mar 29, 2019 02:56 pm ET
IIROC Trading Halt - HLS
TORONTO, March 29, 2019 /CNW/ - The following issues have been halted by IIROC:
Mar 21, 2019 06:30 am ET
HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results
Revenue of $61.4 million, Adjusted EBITDA of $41.1 million and Cash from Operations of $32.7 million for the year-ended December 31, 2018 REDUCE-IT™ cardiovascular outcomes study of Vascepa®, for which HLS has in-licensed exclusive Canadian rights, exceeded primary endpoint demonstrating an approximately 25% relative risk reduction in major adverse cardiovascular events Debt refinancing co-led by JPMorgan Chase Bank, N.A. and Silicon Valley Bank; annual interest savings estimated at $10.0 million Established a quarterly dividend policy of C$0.05 per common share Subsequent to year-end, named
Mar 20, 2019 10:37 am ET
HLS Therapeutics Inc. Opens the Market
TORONTO, March 20, 2019 /CNW/ - William Wells, Executive Chairman, alongside Greg Gubitz, CEO, HLS Therapeutics Inc. (HLS), joined joined Dani Lipkin, Innovation Sector Head, Capital Formation, Toronto Stock Exchange and TSX Venture Exchange, to open the market. Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS Therapeutics Inc. graduated and commenced trading on Toronto Stock Exchange on February 7, 2
Mar 19, 2019 06:32 am ET
HLS Therapeutics Announces Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™
Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show Relative Benefits of Vascepa Usage Grow Over Time TORONTO, March 19, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Amarin Corporation plc (NASDAQ:AMRN), presented new data from its landmark cardiovascular outcomes study of its prescription therapy, Vascepa® (icosapent ethyl), the REDUCE-IT™ study, showing that Vascepa provided a statistically significant 30% ris
Mar 19, 2019 06:30 am ET
HLS Therapeutics Announces High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Atherosclerotic Cardiovascular Disease
TORONTO, March 19, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that on March 16, 2019, Amarin Corporation plc (NASDAQ:AMRN), released the presentation of data and analysis which concluded that over nine million atherosclerotic cardiovascular disease (ASCVD) events are projected to occur in the United States within the next ten years in adults aged 40-79 for whom ASCVD is not established. Over three million of these events are projected to occur in persons with
Mar 14, 2019 06:30 am ET
HLS Therapeutics Licenses and Files 'Athelas One' Point-of-Care Device
From a single drop of blood from the tip of a finger, the point-of-care technology generates white blood cell counts and neutrophils numbers in minutes When approved in Canada, the Athelas One technology could help lower the most commonly cited barrier for using clozapine among those who could benefit from it Upon its approval, the technology will become part of the Clozaril Support and Assistance Network (CSAN®) and made available to Canadian Institutions and HCPs under the name CSAN® ProntoTM TORONTO, March 14, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a spec
Mar 07, 2019 05:30 am ET
HLS Therapeutics to Host 2018 Fourth Quarter and Year-End Financial Results Conference Call
TORONTO, March 7, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its fourth quarter and year-end 2018 financial results by press release at 6:30 am Eastern Time on Thursday, March 21, 2019. The Company will hold a conference call that same day at 8:30 am Eastern Time to discuss its results. The call will be hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Mr. Tim Hendrickso
Feb 19, 2019 05:30 am ET
HLS Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
TORONTO, Feb. 19, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Greg Gubitz, the Company's Chief Executive Officer, is scheduled to present a general company update at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, 2019, at 10:00 a.m. Eastern Time in New York City.
Feb 06, 2019 05:30 am ET
HLS Therapeutics Announces Graduation to the Toronto Stock Exchange
TORONTO, Feb. 6, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, is pleased to announce that it has received final approval for the listing of the Company's common shares (the "Common Shares") on the Toronto Stock Exchange ("TSX").
Jan 29, 2019 05:30 am ET
HLS Therapeutics Receives Conditional Approval to Graduate to the Toronto Stock Exchange
TORONTO, Jan. 29, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it has received the conditional approval of the Toronto Stock Exchange ("TSX") to graduate from the TSX Venture Exchange to list the Company's common shares on the TSX.
Nov 15, 2018 05:30 am ET
HLS Therapeutics Announces Q3 2018 Financial Results
REDUCE-IT™ cardiovascular outcomes study of Vascepa®, for which HLS has in-licensed exclusive Canadian rights, exceeded primary endpoint demonstrating an approximately 25% relative risk reduction Debt refinancing co-led by JPMorgan Chase Bank, N.A. and Silicon Valley Bank; annual interest savings estimated at $10.0 million Establishment of a dividend policy providing for payment of quarterly dividends of C$0.05 per common share Revenue of $15.3 million and $44.8 million in the three- and nine-month periods ended September 30, 2018 Cash from operations of $6.4 million and $21.6 million in the
Nov 12, 2018 05:30 am ET
HLS Therapeutics Announces that Amarin's Vascepa ® (icosapent ethyl) Demonstrates 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attack and Stroke in REDUCE-IT™, whic
Cardiovascular Death Reduced by 20% Fatal or Nonfatal Heart Attacks Reduced by 31% Fatal or Nonfatal Stroke Reduced by 28% Urgent or Emergent Coronary Revascularization Reduced by 35% Hospitalization for Unstable Angina Reduced by 32% Number Needed to Treat for Primary Composite Endpoint: 21 HLS has the Exclusive Rights to Vascepa for the Canadian Market TORONTO, Nov. 12, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V:HLS) announces that Amarin Corporation plc (NASDAQ:AMRN) released primary results from the Vascepa® (icosapent ethyl) cardiovascular ("CV") outcomes trial,
Nov 01, 2018 06:30 am ET
HLS Therapeutics to Host 2018 Third Quarter Results Conference Call
TORONTO, Nov. 1, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in CNS and Cardiovascular markets, announces that it will release its third quarter 2018 financial results by press release at 6:30 am Eastern Time on Thursday, November 15, 2018. The Company will hold a conference call that same day at 8:30 am Eastern Time to discuss its results. The call will be hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Mr. Tim Hendrickson, Chief Financial Officer.
Sep 24, 2018 05:30 am ET
HLS Therapeutics Announces that Amarin's REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint
REDUCE-IT is First Outcomes Study to Assess Treatment of Patients with LDL-C Controlled by Statin Therapy, Persistent Elevated Triglycerides and Other Cardiovascular Risk Factors Results Specific to Pure EPA Vascepa at 4 Grams Daily HLS has the Rights to Vascepa for the Canadian Market Amarin to Host Conference Call Scheduled for Today, Monday September 24, 2018 at 8:00 am ET TORONTO, Sept. 24, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V:HLS) announces that earlier today, Amarin Corporation plc (NASDAQ:AMRN), issued topline results from the Vascepa® cardiovascular ("C
Sep 12, 2018 09:02 am ET
Silicon Valley Bank Serves as Joint Lead Arranger for $125 Million Financing for HLS Therapeutics
TORONTO, Sept. 12, 2018 /PRNewswire/ -- Silicon Valley Bank (SVB), the bank of the world's most innovative companies and their investors, today announced that it co-led a $100 million senior secured term loan and $25 million senior secured revolver for HLS Therapeutics Inc. (TSX-V: HLS), a specialty pharmaceutical company specializing in Central Nervous System ("CNS") and Cardiovascular markets. This financing will support the refinancing of existing debt and provide working capital for the company.
Sep 06, 2018 06:30 am ET
HLS Therapeutics Appoints Tim Hendrickson as CFO
TORONTO, Sept. 6, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system ("CNS") and cardiovascular markets, announces that it has appointed Mr. Tim Hendrickson, the Company's Vice President, Finance & Administration, to the role of Chief Financial Officer ("CFO"), effective immediately.
Aug 22, 2018 06:08 pm ET
HLS Therapeutics Announces Grant of Stock Options
TORONTO, Aug. 22, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system ("CNS") and cardiovascular markets, announces that it has granted, effective today, an aggregate of 538,506 stock options (each an "Option") to certain directors, officers, employees and consultants of the Company in accordance with the Company's amended and restated stock option plan. Each Option is exercisable into one common share (a "Share") of the Company at a price of $8.34 per Share for a period of seven years from the da
Aug 15, 2018 06:30 am ET
HLS Therapeutics Announces Q2 2018 Financial Results
Revenue of $16.3 million, Net Loss of $0.6 million and Adjusted EBITDA of $11.0 million, which were all in line with expectations
Debt refinancing co-led by JPMorgan Chase Bank, N.A. and Silicon Valley Bank; interest savings estimated at $10.0 million per year
Establishment of a dividend policy providing for payment of quarterly dividends of CDN$0.05 per common share and declaration of initial quarterly dividend of CDN$0.05 per common share
TORONTO, Aug. 15, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in Centr
Jul 30, 2018 06:30 am ET
HLS Therapeutics to Host 2018 Second Quarter Results Conference Call
TORONTO, July 30, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in CNS and Cardiovascular markets, announces that it will release its second quarter 2018 financial results by press release on Wednesday, August 15, 2018, prior to market open. The Company will subsequently hold a conference call that same day, Wednesday, August 15, at 8:30 am Eastern Time hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Mr. Tim Hendrickson, VP Finance and Administration. A
Jun 25, 2018 06:30 am ET
HLS Therapeutics Reports Annual Meeting Results
TORONTO, June 25, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces voting results for the election of directors at its Annual Meeting of Shareholders held on June 22, 2018 in Toronto, Ontario.
Jun 15, 2018 06:30 am ET
HLS Therapeutics to Host Annual Shareholder Meeting
TORONTO, June 15, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces details of its upcoming Annual Meeting of Shareholders.
May 30, 2018 06:30 am ET
HLS Therapeutics Enters into Automatic Share Purchase Plan
TORONTO, May 30, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces that it has entered into an automatic share purchase plan (the "ASPP") with a designated broker in order to facilitate repurchases of the Company's common shares ("Common Shares") under its previously announced normal course issuer bid (the "NCIB"). The ASPP has been approved by the TSX Venture Exchange ("TSXV") and will be implemented effective May 30, 2018.
May 16, 2018 06:30 am ET
HLS Therapeutics Announces Q1 2018 Financial Results
Commenced trading on the TSX Venture Exchange (Toronto Stock Exchange)
Revenue of $13.2M in Q1 2018 vs $15.6M in Q1 2017. Clozaril generates year-over-year growth; Absorica royalties reflect distributor destocking to bring supplies in-line with future normalized demand
As at the end of Q1, debt repaid since inception totaled $40.8 million and debt outstanding was $144.2 million
Cash and cash equivalents $53.8 million at end of Q1
Established Normal Course Issuer Bid post quarter-end
TORONTO, May 16, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pha
May 09, 2018 05:00 pm ET
HLS Therapeutics Announces Normal Course Issuer Bid
TORONTO, May 9, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces that the TSX Venture Exchange ("TSXV") has approved the Company's Notice of Intention to Make a Normal Course Issuer Bid ("NCIB"). Pursuant to the NCIB, HLS may, if considered advisable, purchase for cancellation through the facilities of the TSXV and/or permitted alternative trading systems, from time to time over the next 12 months, up to an aggregate of 1,371,495 of its issued and outstanding common shares (each, a "Common Share"), being 5% of the issued and outstanding Common Shares as of M
May 09, 2018 06:30 am ET
HLS Therapeutics to Host 2018 First Quarter Results Conference Call
TORONTO, May 9, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in CNS and Cardiovascular markets, announces that it will release its first quarter 2018 financial results by press release on Wednesday, May 16, 2018, prior to market open. The Company will subsequently hold a conference call that same day, Wednesday, May 16, at 8:30 am Eastern Time hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Tim Hendrickson, VP Finance and Administration. A question and
May 07, 2018 06:30 am ET
HLS Appoints Ryan Lennox as General Counsel
TORONTO, May 7, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in CNS and Cardiovascular markets, announces that Mr. Ryan C. Lennox has been named General Counsel. Reporting to the CEO, the General Counsel role will focus on supporting and enhancing the Company's acquisition efforts, corporate governance directives and general legal requirements.
Apr 26, 2018 06:30 am ET
HLS Therapeutics Announces Partial Redemption of Preferred Shares
TORONTO, April 26, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces that it intends to redeem 9,321,492 (71.83%) of the Company's outstanding Class A preferred shares ("Preferred Shares") on May 9, 2018 on a pro rata basis (the "Partial Redemption"). The shares will be redeemed at a price of CDN $0.61149 per share, for a total redemption payment of CDN $5.7 million (the "Aggregate Redemption Payment").
Apr 20, 2018 06:30 am ET
HLS to Present at the 2018 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 20, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), an emerging specialty pharmaceutical company, announces that Greg Gubitz, CEO, will present at the Bloom Burton & Co. Healthcare Investor Conference, which takes place May 2 - May 3, 2018 at the Sheraton Centre Hotel in downtown Toronto. HLS will present on Wednesday May 2, 2018, at 1:30 p.m. Eastern Time, and will host investor meetings throughout the course of the conference.
Mar 29, 2018 06:30 am ET
HLS Therapeutics Announces Fiscal 2017 Financial Results
Revenue was $75.1 million, a 39% increase year-over-year
Cash generated from operations was $27.2 million, a 25% increase year-over-year
Reverse Take-Over and listing on TSX-V completed post year end
CDN $25.0 million in capital added with Reverse Take-Over
TORONTO, March 29, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) an emerging specialty pharmaceutical company announces the financial results for the three-month and twelve-month periods ended December 31, 2017 for the pre-amalgamation HLS Therapeutics Inc. Unless otherwise noted, all financial results refere
Mar 19, 2018 04:00 pm ET
HLS Therapeutics to Host 2017 Fourth Quarter and Year End Results Conference Call
TORONTO, March 19, 2018 /CNW/ - HLS Therapeutics Inc. (TSXV: HLS) today announced that it will release its fourth quarter 2017 financial results by press release on Thursday, March 29, 2018, prior to market open. The Company will subsequently hold a conference call that same day, Thursday, March 29, at 8:30 am Eastern Time hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Tim Hendrickson, VP Finance and Administration. A question and answer session will follow the corporate update.
Mar 16, 2018 11:00 am ET
HLS Therapeutics Inc. Opens the Market
TORONTO, March 16, 2018 /CNW/ - Bill Wells, Executive Chairman of the Board, HLS Therapeutics Inc. (HLS), joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange, to open the market. HLS Therapeutics Inc. is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established stage branded pharmaceutical products in the North American markets. HLS Therapeutics Inc. commenced trading on TSX Venture Exchange on March 14, 2018.
Mar 13, 2018 04:13 pm ET
IIROC Trading Resumption - GPLY; HLS
VANCOUVER, March 13, 2018 /CNW/ - Trading resumes in:
Mar 12, 2018 06:01 pm ET
HLS Therapeutics Completes Merger with Automodular Corporation
HLS Expected to Begin Trading on the TSXV on March 14, 2018
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
